|Bid||2,377.00 x 0|
|Ask||2,378.00 x 0|
|Day's range||2,343.32 - 2,397.00|
|52-week range||2,158.00 - 2,768.00|
|Beta (5Y monthly)||-0.09|
|PE ratio (TTM)||18.26|
|Earnings date||06 Aug 2021|
|Forward dividend & yield||0.37 (1.53%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
Hikma said it had contacted the Financial Conduct Authority and the London Stock Exchange for a total of 350,000 ordinary shares of 10p each.
GUANGZHOU, China & LONDON, August 27, 2021--Bio-Thera Solutions and Hikma Pharmaceuticals announce exclusive commercialization and license agreement for BAT2206 in the US.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Hikma Pharmaceuticals...